Steve Schonfeld’s Adamas Pharmaceuticals ADMS Stock Holding History

Steve Schonfeld’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,627	Closed	-$207K	–	1047
2018 Q1	$207K	Buy	+8,627	New	+$272K	0.02%	685

Other funds holding ADMS

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Steve Schonfeld's ADMS Position: Q2 2018 in Review

Steve Schonfeld sold out of Adamas Pharmaceuticals (ADMS) in Q2 2018, closing a stake of 8,627 shares — an estimated $207K sold.

Steve Schonfeld first reported a position in ADMS in Q1 2018 and held it in 1 quarter. The position peaked at $207K in Q1 2018. 126 funds tracked by Wall St. Rank hold ADMS as of Q2 2018.

Steve Schonfeld reported no remaining Adamas Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Steve Schonfeld sold 8,627 Adamas Pharmaceuticals shares in Q2 2018, an estimated $207K.
Steve Schonfeld first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 1 quarter.
Steve Schonfeld's Adamas Pharmaceuticals position peaked at $207K in Q1 2018.
126 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2018.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.